Vertex Ventures, Debiopharm, Grove Ventures and Fosun RZ Capital, participated in the USD 33 million Round B investment in Nucleai, an AI-powered spatial biology company, which seeks to transform drug development and clinical treatment decisions through pathology data.
Vertex Ventures, Debiopharm, Grove Ventures and Fosun RZ Capital were represented by Partner Roy Caner and associate Amit Horovitz from Corporate, Hi-Tech, and M&A Department.
To read the full article in hebrew, click on Calcalist.
+97237770120 
